Through an innovative partnership with the Translational Genomics Institute (TGen), the Ochsner Precision Cancer Therapies Program enables cutting-edge treatment to be available to cancer patients across the Gulf South region. This program has made early (Phase I and II) clinical cancer trials a viable option within their local community, while driving molecular diagnostic and clinical strategy, including next generation sequencing of tumor specimens.
Age-adjusted mortality rates from cancer are higher in Louisiana than the national average. Every day, 70 Louisianans receive a cancer diagnosis, and 23 Louisianans die of cancer.
In April 2017, the Ochsner Cancer Institute of New Orleans launched a program the aims to change that, helping make it one of this year’s ACCC Innovator Award honorees. To date, it remains the only program between Houston and Birmingham dedicated to providing access to early-phase clinical trials for patients with cancer.
Read Full Story
Two years ago, Ochsner Health System, the leading healthcare provider in Louisiana, made a bold move in opening the region’s only early phase cancer clinical trials program. From the beginning, it was clear that identifying a partner with complementary experience and expertise was critical to accelerating the program’s development. After much research and consideration, Ochsner partnered with the Translational Genomics Research Institute (TGen) of Phoenix, Ariz., a leading innovator in the fi eld. The Ochsner Precision Cancer Therapies Program has rapidly grown to be an outstanding success.
Read Full Story